Дезурик is a medication utilized in the management of specific chronic conditions characterized by immune system activity and inflammation. The treatment is approved to assist in the mitigation of moderate to severe symptoms associated with active rheumatoid arthritis and certain progressive forms of psoriatic disease. It helps address persistent joint swelling and tenderness, which may ultimately support the preservation of joint function. In clinical practice, Дезурик may be considered when initial therapies have not provided adequate symptom relief.

This medication is primarily indicated for adults facing these ongoing conditions. The therapeutic goal is to help patients achieve and maintain reduced disease activity.

---

Quick Fact: Relief for Joint Discomfort

Eligibility Scope

Classification	Eligible Populations (Label-Based)	Non-Eligible Populations (Restrictions)
Populations Allowed	Adults (age ge 18 years). Patients with mild or moderate hepatic impairment. Patients with any degree of renal impairment.	Patients with severe hepatic impairment (Child-Pugh C) are not recommended.
Pediatric patients (under 18 years) as safety is not established.
Contraindicated	N/A	Patients with a history of hypersensitivity to the active substance or excipients. Patients with a clinically important active infection, including active Tuberculosis (TB).

---

Official Eligibility Statements

• Absolute Exclusion: Use is contraindicated in patients with a prior hypersensitivity reaction or a clinically important active infection, such as active TB.
• Conditional Use: Prior to initiation, patients must be evaluated for TB infection. Treatment for latent TB must be completed before use. Caution is advised for patients aged ge 75 years.
• Reproductive Status: Available human data for pregnancy are insufficient to evaluate a risk, and use is generally advised against. For lactation, excretion into human milk is unknown, and a risk to the newborn cannot be excluded.
• Restrictions: Use in combination with other potent immunosuppressants and the administration of live vaccines are not recommended.

---

Connection to the Overall Eligibility Profile

The official regulatory documents establish that the eligible population for Дезурик is strictly limited to adults who do not have certain active infections or a history of hypersensitivity to the medicine. Eligibility is restricted based on specific criteria, including pre-treatment TB screening, the severity of liver impairment, and the status of pregnancy or lactation.

Interactions with other medicines and products

Regulatory documentation confirms that the use of Дезурик (Deucravacitinib) with certain other medicines is subject to specific constraints based on pharmacodynamic and pharmacokinetic considerations.

Documented Interaction Restrictions

Co-administration with other potent immunosuppressants, which includes substances like Cyclosporine or Azathioprine, is officially not recommended. This restriction is due to the potential for increased systemic immunosuppression.

Furthermore, the official prescribing information advises that co-administration with live vaccines should be avoided. This restriction is based on the risk of infection from the vaccine itself, given the drug's mechanism.

Interaction Type	Official Regulatory Statement
Potent Immunosuppressants	Not recommended
Live Vaccines	Avoid

Pharmacokinetic Profile and Administration

Дезурик exhibits a low risk of clinically relevant pharmacokinetic interactions. Regulatory review confirms that co-administration with strong inhibitors or inducers of major CYP enzymes, such as Fluvoxamine or Rifampin, is not expected to necessitate a dose adjustment for either medicine. There are no mandatory timing or separation requirements specified for administration with other products.

This medication may be taken with or without food, as the observed minor changes in maximum plasma concentration are not considered clinically significant. Use is not recommended in patients with severe hepatic impairment, which is a population-specific consideration due to the potential for altered clearance.

How Дезурик Works

---

Дезурик acts as a highly selective inhibitor of Tyrosine Kinase 2 (TYK2), a member of the Janus kinase (JAK) family. This action is mediated through an allosteric mechanism: the molecule binds specifically to the regulatory pseudokinase domain (JH2) of TYK2, inducing a conformational change that stabilizes the enzyme in an inactive state. This distinct binding profile confers specificity for TYK2, distinguishing its interaction from other Janus kinase family members (JAK1, JAK2, JAK3).

TYK2 is essential for transducing signals from specific pro-inflammatory cytokines, including Interleukin (IL)-12, IL-23, and Type I Interferons. By inactivating TYK2, Дезурик effectively suppresses the signaling cascades initiated by these cytokines. The resultant effect is a reduction in the downstream phosphorylation and activation of STAT proteins, consequently limiting the transcription of genes associated with inflammatory processes.

This targeted interruption of key cytokine signaling sequences modifies early molecular steps within affected pathways. The mechanism influences feedback regulation, leading to an attenuation of overall immune cell signaling and the modulation of systemic physiological outcomes.

How to Use Дезурик: Administration Guidelines

Дезурик (Deucravacitinib) administration follows a non-titrated, fixed-dose schedule. This section details the standardized administration rules and procedural steps for the use of the medication.

---

Administration Scope

Instruction	Detail
Route of administration	Oral (by mouth).
Dosing schedule	Fixed dose of 6 mg (milligrams). No initial dose titration is required.
Timing in relation to meals (if applicable)	May be taken with or without food.
Preparation requirements (if applicable)	The tablet must be swallowed whole. It must not be crushed, cut, or chewed.
Age-group administration rules	Approved for use in adults only. Use is not recommended for adult patients with severe hepatic impairment (Child-Pugh C).
Missed-dose rules	If a dose is missed, administer it as soon as possible. If it is nearly time for the next scheduled dose, skip the missed dose and resume the regular once-daily schedule.
Special procedural conditions	Prior to initiation, evaluation for active and latent tuberculosis (TB) infection is required. The use of live vaccines must be avoided during treatment.

---

Resulting Procedural Structure

The administration protocol involves specific steps before the daily dosing begins:

• Step 1: Complete necessary pre-treatment evaluations, including TB screening, and update age-appropriate immunizations, ensuring live vaccines are avoided.
• Step 2: Begin treatment with the fixed 6 mg oral tablet.
• Step 3: Administer the tablet once daily (QD), swallowing it whole, regardless of mealtime, for the continuous management of the condition.

This protocol ensures standardized use and eliminates the need for dose adjustment based on food intake or degree of renal function.

Research Evidence: Overview of Studies for Дезурик (Deucravacitinib)

Evidence for Use in Moderate-to-Severe Plaque Psoriasis

The clinical research program for this medicine in skin conditions primarily consists of large, international, short-term and intermediate-term Randomized Controlled Trials (RCTs). These trials included thousands of adult patients with moderate-to-severe plaque psoriasis. Researchers examined how symptoms evolved in the observed populations by focusing on standardized measures of skin clearance, including the Psoriasis Area and Severity Index (PASI 75 and PASI 90) and the Static Physician’s Global Assessment (sPGA 0/1), relevant in evidence describing how symptoms are measured. The research reports measurements of the proportion of patients in the active treatment groups who achieved specific skin clearance milestones compared to the placebo group. Comparative evidence is limited against other types of systemic treatments, and long-term effects are not fully established beyond the intermediate follow-up periods of the core trials.

---

Evidence for Use in Active Psoriatic Arthritis (PsA)

The clinical research program for Active Psoriatic Arthritis (PsA), a condition marked by functional limitations, also involved pivotal, multi-center, double-blind RCTs. These studies evaluated the medicine in adult patients, including those who had not previously used a biologic disease-modifying anti-rheumatic drug (bDMARD-naïve). The primary measures used were the American College of Rheumatology response criteria (ACR20), relevant in evidence describing how symptoms are measured for joint conditions. Studies reported measurements of the proportion of patients achieving the ACR20 response criterion in the active treatment group compared to the placebo group after the initial period.

Key limitations include that data on the long-term inhibition of structural joint damage are still emerging. Comparative evidence against other systemic treatments is also limited.

---

Understanding Long-Term Studies and Durability of Response

Patients who completed the core RCTs were often invited to participate in open-label Long-Term Extension (LTE) studies. These LTEs were used in research exploring how symptoms change over time. Long-term extension studies provided follow-up for some patients for up to five years. However, these extension studies are non-randomized, meaning the results apply only to the populations studied who chose to continue treatment, and certainty remains low when trying to generalize these findings.

Key Studies & References Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Common questions about Дезурик (FAQ)

---

Q: Is it normal to have a gout flare-up when first starting Дезурик?

Regulatory documents indicate that Дезурик (Deucravacitinib) is approved for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis, not for gout. Official product information does not address the relationship between this medication and gout flares. Concerns about specific medical conditions, such as gout, are best addressed through consultation with a healthcare professional.

---

Q: Why might a doctor prescribe another medicine to take with Дезурик at the beginning?

Clinical trials for this medication allowed the use of certain other treatments for the target condition, such as some non-biologic topical medicines, depending on the patient’s needs. However, official information strongly advises against co-administration with other potent immunosuppressants, such as cyclosporine. Combination treatment with this medication is based on a healthcare professional's assessment of individual need.

---

Q: Why do people sometimes call Дезурик by other names?

Дезурик is a specific brand name used in certain regions for the active ingredient, Deucravacitinib. In other countries, this same active ingredient may be marketed under a different brand name, such as Sotyktu. This is common practice for medications sold globally.

---

Q: What kind of skin reactions related to Дезурик are considered serious?

Official safety documents highlight the potential for serious adverse reactions, including serious infections like Herpes Zoster (shingles). Official labeling restricts use in patients with a history of hypersensitivity to the medication's components. It is important to know that minor skin issues like acne and folliculitis are listed as common adverse reactions.

---

Q: Can a sudden stop of Дезурик cause problems?

Clinical research has examined what happens when patients discontinue the medication. Studies indicate that stopping treatment can lead to a loss of the achieved clinical response for the underlying condition over a period of months. The long-term extension studies suggest the medication's primary use is for continuous management of the underlying condition as defined by regulatory approval.

---

Q: Does taking Дезурик mean I will never have a gout attack again?

This medication is a selective TYK2 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. It is not approved for the management or prevention of gout. Therefore, official product information does not claim or suggest that the medicine would prevent gout attacks.

---

Q: How quickly does Дезурик start working to lower uric acid levels?

Дезурик is not approved as a medicine to lower uric acid. For its approved use in psoriasis, clinical trial data showed signs of efficacy, measured by standardized assessment tools, as early as one month into treatment. Significant clinical improvement was observed by Week 16 in a high proportion of patients.

---

Q: If I start taking Дезурик, how long will it take before all my gout symptoms are gone?

Official regulatory documents confirm that Дезурик is not approved to treat gout symptoms. For its intended uses in psoriasis and psoriatic arthritis, trials reported that a high proportion of patients achieved co-primary endpoints (measures of clinical response) after approximately 16 weeks of continuous treatment.

---

Q: Does taking Дезурик mean I can stop following a low-purine diet?

Дезурик is approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis, not for gout management. Official regulatory labeling does not include specific guidance or mandatory restrictions concerning the use of a low-purine diet.

---

Q: Do I need to keep taking Дезурик even if I feel fine and haven't had a gout attack in months?

This medicine is generally intended for the continuous management of the underlying immune condition. Regulatory guidance advises that if a patient shows no evidence of therapeutic benefit after 24 weeks, the prescriber should consider discontinuation. The decision to continue treatment is based on a periodic assessment of the patient's condition and therapeutic benefit.

---

Q: What is the difference between Дезурик and Febuxostat (or other similar medicines)?

Дезурик is a selective Tyrosine Kinase 2 (TYK2) inhibitor approved for the treatment of certain chronic immune-mediated diseases like psoriasis. In contrast, Febuxostat is a xanthine oxidase inhibitor used to lower uric acid levels for the treatment of gout. These two medicines belong to distinct pharmacological classes and treat different conditions.

---

Q: Why is it not recommended to use Дезурик to treat high uric acid levels if I don't have symptoms (asymptomatic hyperuricemia)?

Official regulatory approval for Дезурик is strictly limited to the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. The safety and effectiveness of the medication for the treatment of asymptomatic hyperuricemia have not been established in clinical trials.

---

Q: Does Дезурик have any effect on my cholesterol or heart health?

Official safety data reported that a common adverse reaction was an increase in blood triglycerides. The official labeling also includes a warning about the risk of thrombosis (blood clots), specifically Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE). Monitoring of these factors is generally part of the standard clinical assessment for patients using this medication.

---

Q: Why do some people experience initial gastrointestinal upset (nausea/diarrhea) when starting Дезурик?

Official safety documentation lists both diarrhoea and nausea as common adverse reactions that were frequently reported during clinical trials. These are known and expected side effects that occurred in a certain percentage of patients during the studies.

---

Q: What is the general expectation for lab tests while on Дезурик?

The official safety profile reports that laboratory testing commonly showed changes such as lymphopenia (a decrease in a type of white blood cell) and increased blood creatine phosphokinase (CPK). Increases in triglycerides and liver enzymes have also been noted. The regular monitoring of these parameters is consistent with the standard clinical guidance for this medication.

---

Q: How is the action of the active ingredient of Дезурик different from its active metabolite in the body?

The active substance, Deucravacitinib, is known to have an active metabolite (a substance created when the body processes the drug) that contributes to the overall effect. Official information indicates that both the parent drug and the metabolite function as selective TYK2 inhibitors, contributing to the total therapeutic action.

---

Q: Are there different forms of Дезурик (e.g., tablets vs. IV injection) and what are they used for?

According to official regulatory sources, Дезурик is available only as a 6 mg oral tablet for its approved indications. There are no other approved dosage forms, such as IV injections, currently mentioned in the official product information.

---

Q: Does Дезурик work by dissolving existing uric acid crystals?

Дезурик is a selective TYK2 inhibitor and is not approved for gout or for managing uric acid levels. The drug works by blocking specific inflammatory signaling pathways in the body, which is a mechanism distinct from dissolving existing uric acid crystals.

---

Q: If I am undergoing chemotherapy, why might a doctor prescribe Дезурик?

The official approved uses for Дезурик are limited to the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. The safety and effectiveness of this medication in patients undergoing chemotherapy have not been established or approved by regulatory bodies.

Storage and Disposal Information

Official regulatory information for Дезурик (Deucravacitinib) mandates specific requirements for storage and handling to maintain product integrity and safety.

Classification	Regulatory Requirement
Storage Temperature	Store at room temperature, which is between 68 F to 77 F (20 C to 25 C).
Temperature Excursions	Permitted between 59 F and 86 F (15 C and 30 C) for brief periods.
Protection & Handling	Store away from moisture and excess heat. The product must be kept from freezing.
Packaging Rules	Must be kept in the original container and stored with the container tightly closed.
Child Safety	Keep out of the sight and reach of children.
Disposal Instructions	Any unused or expired product should be disposed of in accordance with local requirements. The medicine should not be thrown away via wastewater or household waste.